Post by Alira Health

Have you seen this recent nuclear medicine study? Alira Health experts contributed to the study that evaluates [18F]-DCFPyL for detecting prostate cancer recurrence and provides a cost–consequence comparison with alternative PET radiotracers in Spain.   Prostate cancer is the second most diagnosed malignancy among males worldwide, with approximately 1.4 million new cases in 2020. Despite receiving early treatment, between 20% and 50% of men with prostate cancer experience biochemical recurrence within 10 years of the initial definitive therapy, marked by increasing serum prostate-specific antigen levels without a detectable metastatic disease on conventional imaging, thus complicating clinical decision-making.    [18F]-DCFPyL offers a cost-saving option for biochemical recurrence detection within the Spanish National Healthcare System by reducing the number of unnecessary therapies, the cost of false positives, and repeat testing compared with alternative radiotracers. These improvements support the potential for better diagnostic outcomes and more informed downstream clinical decision-making.   Dive into the study via the Journal of Market Access & Health Policy: https://lnkd.in/dqpsGP3p   Alira Health's expert authors: Mrunmayee Godbole, Rithvik Badinedi